Plain-English translation of NCT07167160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether camrelizumab, an immunotherapy medication, works better when combined with standard chemotherapy to prevent cervical cancer from coming back after surgery. The study focuses on patients whose cancer has spread to nearby lymph nodes. Researchers want to see if adding this new immunotherapy to chemotherapy can improve long-term outcomes for these patients.
Cervical cancer that has spread to lymph nodes is more likely to return even after surgery, and current treatment options don't work for everyone. This trial is testing whether this medication can boost the body's immune system to fight any remaining cancer cells and reduce the risk of the cancer coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the combination treatment of camrelizumab and chemotherapy as follow-up care after your surgery. The treatment would be given over several months in cycles, likely administered at the hospital or clinic. You would have regular visits for infusions, blood work, imaging scans, and check-ups to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Enrollment target
~59 participants
Started
March 2025
Primary completion
December 2026
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.